Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.

× No keyword cloud information.

6 in total

1. Rosiglitazone, but not epigallocatechin-3-gallate, attenuates the decrease in PGC-1α protein levels in palmitate-induced insulin-resistant C2C12 cells.

Authors: Mohammad Hassan Karimfar; Karimeh Haghani; Azar Babakhani; Salar Bakhtiyari
Journal: Lipids Date: 2015-04-18 Impact factor: 1.880

2. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

Authors: Kimihiko Matsusue; Martin Haluzik; Gilles Lambert; Sun-Hee Yim; Oksana Gavrilova; Jerrold M Ward; Bryan Brewer; Marc L Reitman; Frank J Gonzalez
Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808

Review 3. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors: Antona J Wagstaff; Karen L Goa
Journal: Drugs Date: 2002 Impact factor: 9.546

4. PPARγ regulates meibocyte differentiation and lipid synthesis of cultured human meibomian gland epithelial cells (hMGEC).

Authors: Sun Woong Kim; Yilu Xie; Paul Q Nguyen; Vickie T Bui; Kelly Huynh; Jonathan S Kang; Donald J Brown; James V Jester
Journal: Ocul Surf Date: 2018-07-07 Impact factor: 5.033

Review 5. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.

Authors: L Romayne Kurukulasuriya; James R Sowers
Journal: Cardiovasc Diabetol Date: 2010-08-30 Impact factor: 9.951

6. Identification of a proliferator-activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus.

Authors: Ren Wang; Lihua Dai; Jinjin Chen
Journal: Exp Ther Med Date: 2014-12-01 Impact factor: 2.447

6 in total